Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support, and research. Dedicated to addressing the unmet needs of the Chronic Lymphocytic Leukemia (CLL) community,
our goal is to provide real, recent and relevant information and to be the “go to place” for CLL patients and caregivers.
What’s New in CLL?
- Dr. Jennifer Brown from Harvard shares some of the subtleties of correctly diagnosing CLL in our interview from ERIC 2018 in Barcelona.
- ASH 2018 had so much important CLL research, but perhaps the most important abstract was the ECOG trial that compared FCR to ibrutinib plus rituximab (IR) for frontline treatment in chronic lymphocytic leukemia. The strong superiority of IR has major practice changing implications that we will be reporting on in this interview with Dr. Stilgenbauer and in other articles over the next weeks.
- Welcome to the Fourth 2018 Issue of The CLL Society Tribune!
- There are many powerful medications for CLL and even more potent combinations. In Dr. Koffman’s ASH 2018 interview with Professor Hillmen we learn that the timing of when the drugs are given may determine their efficacy.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. The CLL Society is launching a program to provide free second opinions for CLL patients who have not had or who are not able to secure such access. Find out more about this program.
Research Results
The CLL Society regularly polls CLL patients for feedback about educational needs, clinical trial participation, treatment status, self-assessed knowledge of CLL, sources of information, and more.
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL